X @Bloomberg
Bloomberg·2026-07-27 11:50
Apnimed, a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering https://t.co/oIZTR1IE5L ...
Apnimed, a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering https://t.co/oIZTR1IE5L ...